Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Alexis Thompson, MD, MPHDr. Alexis Thompson is currently the Hem...
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
-
Augusta University Sickle Cell CenterLocated in Augusta, Georgia, Augusta Uni...
-
UC Davis Health, Department of PediatricsThe Section of Pediatric Hematology/Onco...
-
CMO Speaks: Making ED Care Better for SCD – Progress in 2023Welcome to CMO Speaks, a blog featuring ...
-
Debbie Murray, RN, CPN, CMAC, CHCDebbie Murray is a Certified Nurse Manag...
-
Access to Care, and Emergency Department Utilization for Adults and Adolescents With Sickle Cell Disease: Ascq-Me an...Measurement of access to care and utiliz...
